Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer

Clinical and Experimental Metastasis

Volumn 19, Issue 6, 2002, Pages 527-534

  Konno, Hiroyuki ^a   Baba, Megumi ^a   Shoji, Tuyoshi ^a   Ohta, Manabu ^a   Suzuki, Shohati ^a   Nakamura, Satoshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Colorectal cancer; Cyclooxygenase 2; Invasion; Plasminogen activating system; UPAR

Indexed keywords

CYCLOOXYGENASE 2; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE; UROKINASE RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER INVASION; COLORECTAL CANCER; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TUMOR VASCULARIZATION;

COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOENZYMES; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MICROCIRCULATION; NEOPLASM INVASIVENESS; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, CELL SURFACE; SURVIVAL RATE; TIME FACTORS;

EID: 0036396807     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020392309715     Document Type: Article

References (50)

1. Sano H, Kawahito Y, Wilder RL et al. Expression of cyclooxygenase-1, and -2 in human colorectal cancer Cancer Res 1995; 55: 3785-9.
2. Wolff H, Saukkonen K, Anttila S et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 15: 4997-5001.
3. Tucker ON, Dannenberg AJ, Yang EK et al. Cyclooxygenase-2 expression is upregulated in human pancreatic cancer. Cancer Res 1999; 59: 987-90.
4. Boolbol SK, Dannenberg AJ, Chadburn DA et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996; 56: 2556-60.
5. Sawaoka H, Kawano S, Tsuji S et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998; 274: G1061-7.
6. Tsujii M, Kawano S, Tsujii S et al. Cyclooxygenase regulares angiogenesis induced by colon cancer cells. Cell 1998: 93: 705-16.
7. Fujita T, Minoru M, Takaku K et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998; 58: 4823-6.
8. Shirahama T, Arima J, Akiba S et al. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 2001; 92: 188-93.
9. Takahashi Y, Kawahara F, Noguchi M et al. Activation of matrix metalloprotease-2 in human breast cancer cell line overexpressing cyclooxygenase-1 or -2. FEBS Leu 1999; 460: 145-8.
10. Dano K, Andreasen PA, Grondahl HJ et al. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
11. Mazzieri R, Masiero L, Zanetta et al. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants. EMBO J 1997; 16: 2319-32.
12. Rao JS, Steck PA, Tofilon P et al. Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model. J Neurooncol 1994; 18: 129-38.
13. Keski-Oja J, Lohi J. Tuuttila A et al. Proteolytic processing of the 72,000-Da type IV collagenase by urokinase plasminogen activator. Exp Cell Res 1992; 202: 471-6.
14. Duffy MJ, Reilly D, O'Sullivan C et al. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990; 50: 6827-9.
15. Sumiyoshi K, Serizawa K, Urano T et al. Plasminogen activator system in human breast cancer. Int J Cancer 1992; 50: 345-8.
16. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7.
17. Tsuji M. Kawano S, Sawaoka H et al. Evidence for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostaglandins Leukot & Essent Fatty Acids 1996; 55: 179-83.
18. Nishimura G, Yanoma S, Mizuno H et al. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res 1999: 90: 1152-62.
19. Hara A, Yoshimi N, Niwa M et al. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn J Cancer Res 1997; 88: 600-4.
20. Elder DJ, Halton DE, Hague A et al. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2(COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997; 3: 1679-83.
21. Elder DJ, Halton DE, Crew TE et al. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int J Cancer 2000; 86: 553-60.
22. Huang M, Stolina M, Sharma S et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998; 58: 1208-16.
23. Dohadwala M, Luo J, Zhu L et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001; 276: 20809-12.
24. Chen WS, Wei SJ, Liu JM et al. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodlac. Int J Cancer 2001; 91: 894-9.
25. Ohno R, Yoshinaga K, Fujita T et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 2001; 91: 1876-81.
26. Masferrer JL, Leahy KM, Koki AT et al. Antiangiogeninc and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-11.
27. Sawaoka H, Tsuji S, Tsujii M et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999; 79: 1469-77.
28. Liu XH, Kirschenbaum A, Yao S et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000; 164: 820-5.
29. Abe J, Urano T, Konno H et al. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size. Cancer 1999; 86: 2602-11.
30. Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 1992; 10: 145-55.
31. Costantini V, Sidoni A, Deveglia R et al. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: An immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer 1996; 77: 1079-88.
32. McCabe NP, Angwafo FF 3rd, Zaher A et al. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. Oncol Rep 2000; 7: 879-82.
33. de Witte JH, Foekens JA, Brunner N et al. Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumors. Br J Cancer 2001: 85: 85-92.
34. Nekarda H, Schmitt M, Ulm K et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994; 54: 2900-7.
35. Chambers SK, Ivins CM, Carcangiu ML. Plasminogen activator inhibitor-1 is ah independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 1998; 79: 449-54.
36. Deng G, Curriden SA. Wang S et al. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996; 134: 1563-71.
37. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrinaVb3 binding to vitronectin. Nature 1996; 383: 441-3.
38. Kjoller L, Kanse SM, Kirkegaard T et al. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997; 232: 420-9.
39. Hapke S, Kessler H, Arroyo de Prada N et al. Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J Biol Chem 2001; 276: 26340-8.
40. Khatib AM, Nip J, Fallavollita L et al. Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3. Int J Cancer 2001; 91: 300-8.
41. Dimberg J, Hugander A, Sirsjo A et al. Enhanced expression of cyclooxygensa-2 and nuclear beta-catenin are related to mutations in the APC gene in human colorectal cancer. Anticancer Res 2001; 21: 911-5.
42. Pan MR, Chuang LY, Hung WC. Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett 2001; 508: 365-8.
43. Attiga FA, Fernandez PM, Weeraratna AT et al. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteases. Cancer Res 2000; 60: 4629-37.
44. Masunaga R, Kohno H, Dhar DK et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000; 6: 4064-8.
45. Majima M, Hayashi I, Muramatsu M et al. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Phannacol 2000; 130: 641-9.
46. Cianchi F, Cortesini C, Bechi P et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001; 121: 1339-47.
47. Dempke W. Rie C, Grothey A et al. Cyclooxygenase-2: A novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001; 127: 411-7.
48. Gallo O, Franchi A, Magnelli L et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001; 3: 53-61.
49. Mazar AP. The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anticancer Drugs 2001; 12: 387-400.
50. Konno H, Abe J, Kaneko T et al. Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer. Jpn J Cancer Res 2001; 92: 516-23.